{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010974","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.454161+00:00","generated_at":"2026-05-17T15:45:46.876781+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed","bullets":["Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.","Net loss $95.8M for H1 2025 vs. $39.3M in H1 2024; R&D expense $89.0M including $40M one-time upfront to Lepu BioPharma.","Positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC; final data at WCLC September 2025.","First patient dosed in Phase 1 for ARR-217 (CDH17-targeted ADC) in gastrointestinal tumors by partner Lepu.","Top-line firmonertinib data from FURVENT Phase 3 for EGFR Exon20 insertion expected early 2026; PACC Phase 3 ALPACCA enrollment in 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010974","json":"https://secwatch.observer/filing/0001558370-25-010974.json","markdown":"https://secwatch.observer/filing/0001558370-25-010974.md","text":"https://secwatch.observer/filing/0001558370-25-010974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/0001558370-25-010974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:45:46.876781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}